Abbott Laboratories, US0028241000

Abbott Laboratories stock: Abbott starts VOYAGER valve trial

Published on 11/19/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock enters focus as the company starts a trial for an investigational TAVI system. The device targets aortic stenosis.

New Cardiac Trial Begins

  • The VOYAGER program targets aortic stenosis with an investigational balloon-expandable TAVI system.
  • The software-guided approach adds a new clinical milestone to Abbott's cardiac-device pipeline.
  • Trial execution and later regulatory steps are key watchpoints for investors.
Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott said on Thursday, November 19, 2026, that it had initiated the VOYAGER clinical trial for Encantor, an investigational software-guided balloon-expandable transcatheter aortic valve implantation system intended to treat aortic stenosis. Abbott announced the development in its Abbott MediaRoom.

Clinical Development Milestone

The trial adds a new investigational cardiac-device program to Abbott's development pipeline. The system combines a balloon-expandable valve platform with software guidance, while the stated clinical focus is aortic stenosis.

For investors, the main significance is the expansion of Abbott's cardiac-device activity into another clinical program. Trial execution, eventual study results and subsequent regulatory steps will determine whether the program can develop into a commercial opportunity.

Trading Context

Abbott Laboratories stock last traded at 95.50 euros on Lang & Schwarz at 15:43 CET on Thursday, November 19, 2026. The quote provides the latest market context alongside the newly announced trial.

Abbott Laboratories at a glance

  • Company: Abbott Laboratories
  • ISIN: US0028241000
  • Ticker: ABT
  • Quote: 95.50 euros
  • Venue: Lang & Schwarz
  • Quote time: 15:43 CET, Thursday, November 19, 2026
  • New development: VOYAGER clinical trial for investigational Encantor TAVI system

Broader market developments remain relevant for investors following Abbott Laboratories stock; see Current market reports.

For more company developments, see More news and analyses on Abbott Laboratories stock.

Disclaimer...
en | US0028241000 | ABBOTT LABORATORIES | boerse | 70536757 | bgmi